Bioprocess technology, FHNW School of Life Sciences

Recombinant proteins such as antibodies are up to 1,000 times larger and more complicated molecules than classical drugs such as aspirin. Novel therapies whose administered products rely on viral vectors, exosomes or modified cells are even more complex. The production of these large molecules and cell products is correspondingly difficult, expensive and time-consuming.

The Bioprocess technology group teaches, develops and optimizes such biopharmaceutical production processes to produce sufficient material and, above all, with the desired product quality. New technologies and process approaches as well as traditional cell cultures and purification steps are used to map the entire process chain from the initial cell line to the finished product. Particular attention is paid to innovative measurement and control technology in order to be able to develop production-oriented solutions with automated and interconnected processes.

Our research group is part of the Institute for Pharma Technology and Biotechnology.